Standards For Early Alzheimer’s Drugs Adapted, Not Loosened, FDA’s Katz Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A draft guidance for development of drugs to treat early Alzheimer’s disease does not loosen agency standards, FDA’s neurology products chief asserts. Rather, it is an attempt to establish criteria tailored to the population.
You may also be interested in...
Lilly Shifts Course With Alzheimer’s Drug Solanezumab
In another sign of uncertainty for Alzheimer’s disease drug development, Lilly shakes things up with announcement of design changes for Phase III trial for solanezumab.
Alzheimer’s Placebo May Become Disease-Modifying Drug For Affiris
Biotech shifts development plans after Phase II study shows surprising, but promising, results – albeit in the wrong arm of the study.
Eisai’s Bayesian Alzheimer’s Trial Aims For Quick Proof Of Concept With Fewer Subjects, Lower Cost
Eisai should get the first feedback from an adaptive Phase II trial of BAN2401 in Alzheimer’s patients with mild cognitive impairment in six or seven months, offering the first opportunity to adjust parameters testing dose response and the antibody’s disease-modifying potential or to stop the trial early for futility.